Fulvestrant – ready to start its journey in the breast cancer adjuvant endocrine world?
- 28 February 2005
- journal article
- editorial
- Published by Elsevier in European Journal Of Cancer
- Vol. 41 (3) , 341-343
- https://doi.org/10.1016/j.ejca.2004.09.019
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Endocrine treatment options for advanced breast cancer – the role of fulvestrantEuropean Journal Of Cancer, 2005
- Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized TrialJournal of Clinical Oncology, 2004
- Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of actionBritish Journal of Cancer, 2004
- Selective Estrogen Receptor ModulatorsCancer Research, 2004
- Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American TrialJournal of Clinical Oncology, 2002
- Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine TreatmentJournal of Clinical Oncology, 2002
- Comparison of the Effects of a Pure Steroidal antiestrogen With Those of Tamoxifen in a Model of Human Breast CancerJNCI Journal of the National Cancer Institute, 1995
- Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancerThe Lancet, 1995
- Circumvention of tamoxifen resistance by the pure anti‐estrogen ICI 182, 780International Journal of Cancer, 1993
- STEROIDAL PURE ANTIOESTROGENSJournal of Endocrinology, 1987